News & Events about Zymeworks Inc.
VANCOUVER, British Columbia, May 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Bank of America ...
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will report its first quarter 2023 financial results after market close on May 8, 2023. Following the announcement, management will host a...
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced the appointment of Derek J. Miller to its board of directors effective April 10, 2023. Mr. Miller brings extensive commercial, corporate and business development...
Latest Ratings for ZYME
DateFirmActionFromTo Feb 2022Wells FargoMaintainsOverweight Dec 2021Raymond JamesDowngradesStrong BuyOutperform Dec 2021SVB LeerinkUpgradesMarket PerformOutperform
View More Analyst Ratings for ZYME
View the Latest Analyst Ratings
read more...
Business Wire
3 months ago
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Barclays Global Healthcare Conference. Zymeworks management will participate in...